Seven numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 2 other studies
the abstract, start to end
… yielding a summary relative risk of 1.22 (95% CI, 1.02-1.46) (Table 3 …
… users reported a relative risk of 1.22 (95% CI, 0.86-1.74) [36].
… yielding a summary relative risk of 1.14 (95% CI, 0.86-1.50); we …
… agents, versus metformin was 1.36 (95% CI, 1.17-1.59) [36, 40, …
… those using lower doses (hazard ratio, 1.38; 95% CI, 1.20-1.60) [41].
… users of pioglitazone (relative risk, 1.21; 95% CI, 1.03-1.42), and …
… by Loebstein et al. [40] (relative risk, 2.23; 95% CI, 1.41-3.53) might be …
← favours treatmentfavours comparator →
could be chanceCardiovascular events
RR 1.221.02–1.46
Cardiovascular events
RR 1.220.86–1.74
Cardiovascular events
RR 1.140.86–1.50
Glycemic control
−1.36−1.59 to −1.17
Cardiovascular events
HR 1.381.20–1.60
Adverse events & safety
RR 1.211.03–1.42
Cardiovascular events
RR 2.231.41–3.53
MetforminSulfonylureas & glinidesThiazolidinedionesOther glucose-loweringGlycemic controlCardiovascular eventsAdverse events & safety
Metformin × cardiovascular eventshelps?mixed
unlikelylikely
0.50not counted
Sulfonylureas & glinides × cardiovascular eventshelps?replicated
unlikelylikely
0.96not counted
Thiazolidinediones × cardiovascular eventshelps?mixed
unlikelylikely
0.00not counted
← favours treatmentfavours comparator →
1 / 6